Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme: the STELLAR Study

NCT03025893 is registered in ClinicalTrials.gov with Amsterdam UMC, location VUmc as lead sponsor.

NCT NCT03025893
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03025893 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme: the STELLAR Study
Lead sponsor
Amsterdam UMC, location VUmc
Phase
Phase 2/3
Overall status
Unknown status
Start date
August 31, 2018
Completion date
January 1, 2022
Enrollment
100 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

gbm, glioblastoma, glioblastoma multiforme, glioblastoma, adult, recurrent brain tumor